Skip to main content
Clinical Trials/NCT04603157
NCT04603157
Completed
Not Applicable

Remote Self-training Program for Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Mayo Clinic1 site in 1 country60 target enrollmentJanuary 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postural Orthostatic Tachycardia Syndrome
Sponsor
Mayo Clinic
Enrollment
60
Locations
1
Primary Endpoint
Change Peak Oxygen consumption at 3 months
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this research is to evaluate if a hybrid semi-supervised remote exercise training program can reduce symptoms and improve quality of life and physical fitness in individuals with postural orthostatic tachycardia syndrome (POTS) and determine if this program is more effective than current standard of care.

Detailed Description

To answer these questions, 60 individuals with POTS will be recruited to complete a symptom-limited cardiopulmonary exercise test with measures of cardiac output, autonomic function testing, blood volume measurement, and QOL questionnaires at baseline and following 3-months of treatment. Thirty participants will be randomized to continue with the standard of care which can include lower body and core strengthening, fluids, salt, medications and sometimes exercise. The other thirty participants will be asked to complete at least three exercise training sessions a week (progressing to 3hrs/wk of aerobic and 1hr/wk of strength training) and receive eight supervised training sessions over the 3-month treatment period. All participants will be provided with a polar heart rate monitor which will be linked to a connected health application to allow patients to track any aerobic workout, ensure during a session they are in the correct training zone, and allow the study team to remotely monitor adherence.

Registry
clinicaltrials.gov
Start Date
January 1, 2020
End Date
February 18, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Courtney M. Wheatley

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Must be 18 years old or older
  • Meet diagnosis criteria for POTS = a heart rate increase of ≥ 30bpm with supine to 10 minutes of standing or head-up tilt or heart rate exceeding 120 ppm after 10 minutes of standing or tilt without evidence of orthostatic hypertension (a fall in BP of \> 20/10 mmHg)
  • Been diagnosed with POTS ≥6 months prior to participation in the study (chronic)
  • Female subjects must not be pregnant or trying to become pregnant during duration of study participation
  • Those in exercise training group must be on stable medications for at least 1 month and medication must remain consistent for duration of study participation. For those in the standard of care group, a change in medication will be allowed within the first month following baseline testing, but then must remain consistent until 3-month testing time point.
  • Ehlers-Danlos Syndrome (EDS) patients will be included, but will target equal randomization between treatment groups

Exclusion Criteria

  • Individual is not eligible if they are currently exercising, cut off \>30 minutes of structured exercise/physical activity per week. (assessed by Global Physical Activity Questionnaire)

Outcomes

Primary Outcomes

Change Peak Oxygen consumption at 3 months

Time Frame: baseline and following 3 month intervention

peak oxygen consumption measured from maximal cardiopulmonary exercise testing

Secondary Outcomes

  • Change in heart rate with 10-min Stand test at 3 months(baseline and following 3 month intervention)
  • Change in Functional Ability Score at 3 months(baseline and following 3 month intervention)
  • Change in 36-Item Short Form Health Survey questionnaire (SF-36) at 3 months(baseline and following 3 month intervention)
  • Change in blood volume at 3 months(baseline and following 3 month intervention)
  • Change in Composite Autonomic Symptom Score (COMPASS 31) at 3 months(baseline and following 3 month intervention)

Study Sites (1)

Loading locations...

Similar Trials